Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: CNBC

What happened

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Key facts

  • Reported by CNBC and published Fri, 02 Oct 2026 17:55:26 UTC.

Why it matters

Economic releases and corporate results feed directly into rate expectations, currency moves and equity pricing, so the detail here often matters more to markets than the headline itself.

What to watch next

  • Revisions to the initial figures once fuller data is released
  • How rate expectations and index futures respond
  • Guidance or commentary from the companies and policymakers involved

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

  2. Asos warns customer data may be compromised after ‘unauthorised’ app access

  3. What can I do to protect myself after 'Asos hacked' message?

Sources

The original report was published by CNBC. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at CNBC

Related WorldPing coverage

Asos warns customer data may be compromised after ‘unauthorised’ app accessWorldPing
The Guardian

Asos warns customer data may be compromised after ‘unauthorised’ app access

Shares in fashion company fall nearly 10% after its app systems are accessed by ‘unidentified third party’ Asos is investigating unauthorised access to its app system after shoppers received a notification claiming hackers had “fully compromised” its data.

Brief by WorldPing · Original reporting by The Guardian

Evernorth Sets New XRP Treasury Timeline After Administrative DelayWorldPing
Bitcoin.com

Evernorth Sets New XRP Treasury Timeline After Administrative Delay

Stock market access to Evernorth’s XRP treasury is expected later than previously planned after an administrative delay. The company has revised its merger and Nasdaq trading timetable while maintaining that the setback should not affect completion.

Brief by WorldPing · Original reporting by Bitcoin.com